Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

Cited by (686)

Items 101–200 of 686

1. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment
   Junge Bai, Hongsheng Chen, Xuefeng Bai · 2021 · Journal of Clinical Laboratory Analysis
2. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
   Kentaro Yamazaki, Takeharu Yamanaka, Manabu Shiozawa, Dai Manaka, Masahito Kotaka, Makio Gamoh, Akio Shiomi, Akitaka Makiyama, Yoshinori Munemoto, Toshiki Rikiyama et al. · 2020 · Annals of Oncology
3. Gender and sex differences in colorectal cancer screening, diagnosis and treatment
   Encarnación González‐Flores, Rocio García‐Carbonero, Elena Élez, Eduardo Redondo‐Cerezo, María José Safont, Ruth Vera García · 2025 · Clinical & Translational Oncology
4. Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis
   Masaru Noda, Hirokazu Okayama, Kazunoshin Tachibana, Wataru Sakamoto, Katsuharu Saito, Aung Kyi Thar Min, Mai Ashizawa, Takahiro Nakajima, Keita Aoto, Tomoyuki Momma et al. · 2018 · Clinical Cancer Research
5. Nationwide in‐hospital mortality following colonic cancer resection according to hospital volume in Germany
   Johannes Diers, Johanna Wagner, Philip Baum, S. Lichthardt, C. Kastner, Niels Matthes, Stefan Löb, Harald Matthes, Christoph‐Thomas Germer, Armin Wiegering · 2019 · BJS Open
6. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
   John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris, Spyros Xynogalos, Nikolaos Ziras, A. Athanasiadis, Nikolaos E. M. Androulakis, Athina N. Christopoulou, Michael M. Vaslamatzis, Alexandros S Ardavanis et al. · 2019 · Annals of Oncology
7. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials
   Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy J. Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony Frank Shields et al. · 2022 · Journal of Clinical Oncology
8. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer
   Fausto Petrelli, Roberto Labianca, Alberto Zaniboni, Sara Lonardi, Fabio Galli, Eliana Rulli, Gerardo Rosati, Salvatore Corallo, Monica Ronzoni, Giovanni Gerardo Cardellino et al. · 2020 · JAMA Oncology
9. Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system
   Jeong Mo Bae, Jung Ho Kim, Yoonjin Kwak, Dae‐Won Lee, Yongjun Cha, Xianyu Wen, Tae Hun Lee, Nam‐Yun Cho, Seung‐Yong Jeong, Kyu Joo Park et al. · 2017 · British Journal of Cancer
10. Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells
    Mohammad S. El‐Wetidy, Rehan Ahmad, Islam Rady, Hamed Helal, Mohamed I. Rady, Mansoor‐Ali Vaali‐Mohammed, Khayal Al‐Khayal, Thamer Bin Traiki, Maha‐Hamadien Abdulla · 2021 · Cell Stress and Chaperones
11. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
    Jean‐François Emile, Catherine Julié, Karine Le Malicot, Côme Lepage, Josep M. Tabernero, Enrico Mini, Gunnar Folprecht, Jean‐Luc Van Laethem, Stéphanie Dimet, Camille Boulagnon‐Rombi et al. · 2017 · European Journal of Cancer
12. Molecular Targets for the Treatment of Metastatic Colorectal Cancer
    Romain Cohen, Thomas Pudlarz, Jean-François Delattre, Raphaël Colle, Thierry André · 2020 · Cancers
13. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
    Cohen, Romain, Colle, Raphaël, Pudlarz, Thomas, Heran, Maximilien, Duval, Alex, Svrcek, Magali, André, Thierry · 2021 · Cancers
14. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
    Julien Taïeb, Frank A. Sinicrope, Levi Pederson, Sara Lonardi, Steven R. Alberts, Thomas J. George, Greg Yothers, Eric Van Cutsem, Leonard B. Saltz, Shuji Ogino et al. · 2023 · Annals of Oncology
15. COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
    Frédéric Di Fiore, Olivier Bouché, Côme Lepage, David Sefrioui, Alice Gangloff, Lilian Schwarz, Jean‐Jacques Tuech, Thomas Aparicio, Thierry Lecomte, Camille Boulagnon‐Rombi et al. · 2020 · Digestive and Liver Disease
16. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life
    Måns Stefansson, Peter Nygren · 2016 · Acta Oncologica
17. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version)
    Hideyuki Ishida, Tatsuro Yamaguchi, Kohji Tanakaya, Kiwamu Akagi, Yasuhiro Inoue, Kensuke Kumamoto, Hideki Shimodaira, Shigeki Sekine, Toshiaki Tanaka, Akiko Chino et al. · 2018 · Journal of the Anus Rectum and Colon
18. Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients
    Daniel Brungs, Morteza Aghmesheh, Paul DE SOUZA, Weng Leong Ng, Wei Ming Chua, Martin Carolan, Philip R. Clingan, Emma Healey, June Rose, Tameika Tubaro et al. · 2017 · BMC Cancer
19. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer
    Lisha Wang, Zebing Liu, Kurt W. Fisher, Fei Ren, Jiaojie Lv, Darrell D. Davidson, Lee Ann Baldridge, Xiang Du, Liang Cheng C · 2017 · Human Pathology
20. Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation
    Hung–Hua Liang, Chien‐Yu Huang, Ching-Wen Chou, Precious Takondwa Makondi, Ming‐Te Huang, Po‐Li Wei, Yu‐Jia Chang · 2018 · Life Sciences
21. Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database
    Zhaohui Jin, Jesse G. Dixon, Jack Fiskum, Hiral D. Parekh, Frank A. Sinicrope, Greg Yothers, Carmen Joseph Allegra, Norman Wolmark, Daniel G. Haller, Hans‐Joachim Schmoll et al. · 2021 · JNCI Journal of the National Cancer Institute
22. Synthesis of novel 1,3,4-oxadiazole derivatives as potential antimicrobial agents.
    Rakesh Chawla, Anshu Arora, Manojkumar Parameswaran, Prabodh Chan, Der Sharma, Sukumar Michael, Thengungal Kochupappy Ravi · 2010 · PubMed
23. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
    Priyadarshini Pathak, Gloria Hui Jia Chan, Dustin A. Deming, Cheng Ean Chee · 2024 · American Society of Clinical Oncology Educational Book
24. The Clinical Significance of MiR-429 as a Predictive Biomarker in Colorectal Cancer Patients Receiving 5-Fluorouracil Treatment
    Sheng-jian Dong, Xiaojun Cai, Shujin Li · 2016 · Medical Science Monitor
25. Evolving notions on immune response in colorectal cancer and their implications for biomarker development
    Fabio Grizzi, Gianluca Basso, Elena Monica Borroni, Tommaso Cavalleri, Paolo Pietro Bianchi, Sanja Štifter, Maurizio Chiriva‐Internati, Alberto Malesci, Luigi Laghi · 2018 · Inflammation Research
26. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine
    Sakti Chakrabarti, Jaskanwal Deep Singh Sara, Ronstan Lobo, Rachel A. Eiring, Heidi Diann Finnes, Jessica L. Mitchell, Mindy L. Hartgers, Akiko Okano, Thorvardur Ragnar Halfdanarson, Axel F. Grothey · 2018 · Clinical Colorectal Cancer
27. Improvement of Survival over Time for Colorectal Cancer Patients: A Population-Based Study
    Audrius Dulskas, Vytautas Gaižauskas, Inga Kildušienė, Narimantas Evaldas Samalavičius, Giedrė Smailytė · 2020 · Journal of Clinical Medicine
28. Current and future biomarkers in the treatment of colorectal cancer
    Pieter-Jan AR Cuyle, Hans Prenen · 2016 · Acta Clinica Belgica
29. How I treat stage II colon cancer patients
    Julien Taı̈eb, Mehdi Karoui, Debora Basile · 2021 · ESMO Open
30. The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217)
    Gunnar Folprecht, Anke Reinacher‐Schick, Jürgen Weitz, Céline Lugnier, Anna‐Lena Kraeft, Sarah Wisser, Daniela Ellen Aust, Lukas Weiß, Nikolas C. C. von Bubnoff, Michael Krämer et al. · 2021 · Clinical Colorectal Cancer
31. Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
    Nikolouzakis, Taxiarchis Konstantinos, Chrysos, Emmanuel, Docea, Anca Oana, Fragkiadaki, Persefoni, Souglakos, John, Tsiaoussis, John, Tsatsakis, Aristidis · 2024 · Cancers
32. Dietary Intake of Magnesium or Calcium and Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Patients
    Evertine Wesselink, Renate M. Winkels, Harm van Baar, Anne J. M. R. Geijsen, Moniek van Zutphen, Henk van Halteren, Bibi M. E. Hansson, Sandra A. Radema, Johannes H.W. de Wilt, Ellen Kampman et al. · 2018 · Nutrients
33. Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma
    Xiaojian Ye, Guoqiang Zhang, Hai‐Bin Chen, Yong Li · 2018 · PLoS ONE
34. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
    Timothy J. Iveson, Kathleen Boyd, Rachel S. Kerr, José Antonio Robles‐Zurita, Mark P. Saunders, Andrew H. Briggs, Jim Cassidy, Niels Henrik Holländer, Josep M. Tabernero, Andrew Mark Haydon et al. · 2019 · Health Technology Assessment
35. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
    John C. Flickinger, Jagmohan Singh, Robert D. Carlson, Elinor Leong, Trevor R. Baybutt, Joshua R. Barton, Ellen M. Caparosa, Amanda M. Pattison, Jeffrey A. Rappaport, Jamin W. Roh et al. · 2020 · Journal for ImmunoTherapy of Cancer
36. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials
    Frank A. Sinicrope, Sakti Chakrabarti, Pierre Laurent‐Puig, Luke Huebner, Thomas C. Smyrk, Josep M. Tabernero, Enrico Mini, Richard M. Goldberg, Aziz Zaanan, Gunnar Folprecht et al. · 2020 · European Journal of Cancer
37. Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis
    Gianluca Tomasello, Michele Ghidini, Barbara Galassi, Francesco Grossi, Andrea Luciani, Fausto Petrelli · 2022 · Scientific Reports
38. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)
    Slater, Susanna, Bryant, Annette, Chen, Hsiang-Chi, Begum, Ruwaida, Rana, Isma, Aresu, Maria, Peckitt, Clare, Zhitkov, Oleg, Lazaro-Alcausi, Retchel, Borja, Victoria et al. · 2023 · BMC Cancer
39. Prognostic and predictive role of DNA mismatch repair status in stage II‐III colorectal cancer: A systematic review and meta‐analysis
    Zhujun Deng, Yun Qin, Jing Wang, Gang Wang, Xiaoqiang Lang, Juan Jiang, Kang Xie, Wengeng Zhang, Heng Xu, Yang Shu et al. · 2019 · Clinical Genetics
40. Colorectal cancer and therapy response: a focus on the main mechanisms involved
    Sara Tirendi, Barbara Marengo, Cinzia Domenicotti, Anna Maria Bassi, Vanessa Almonti, Stefania Vernazza · 2023 · Frontiers in Oncology
41. Metformin Inhibits the Urea Cycle and Reduces Putrescine Generation in Colorectal Cancer Cell Lines
    Tao Zhang, Ling Hu, Jiafeng Tang, Hang Xu, Kuan Tian, Mengna Wu, Shiying Huang, Yu-Mei Du, Peng Zhou, Rui-Jin Lu et al. · 2021 · Molecules
42. MSI colorectal cancer, all you need to know
    Clémence Flecchia, Aziz Zaanan, Widad Lahlou, Debora Basile, Chloé Broudin, Claire Gallois, Lorenzo Pilla, Mehdi Karoui, Gilles Manceau, Julien Taı̈eb · 2022 · Clinics and Research in Hepatology and Gastroenterology
43. A modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database
    Xiangxing Kong, Jun Li, Yibo Cai, Yu Tian, Shengqiang Chi, Danyang Tong, Yeting Hu, Qi Yang, Jingsong Li, Graeme J. Poston et al. · 2018 · BMC Cancer
44. Novel Gold(I) Thiolate Derivatives Synergistic with 5-Fluorouracil as Potential Selective Anticancer Agents in Colon Cancer
    Elena Atrián‐Blasco, Sonia Gascón, M.J. Rodrı́guez-Yoldi, Mariano Laguna, Elena Cerrada · 2017 · Inorganic Chemistry
45. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
    Mohamed E. Salem, Jun Yin, Richard M. Goldberg, Levi Pederson, Norman Wolmark, Steven R. Alberts, Julien Taı̈eb, J. L. Marshall, Sara Lonardi, Takayuki Yoshino et al. · 2020 · Annals of Oncology
46. Metformin protects from oxaliplatin induced peripheral neuropathy in rats
    Nicolás W. Martínez, A. Sánchez, Paula Díaz, Richard Broekhuizen, Juan Alejandro Godoy, Sebastián Mondaca, Alejandra Catenaccio, Patricia Macanas-Pirard, Bruno Nervi, Margarita Calvo et al. · 2020 · Neurobiology of Pain
47. Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis
    Yufeng Chen, Zhaoliang Yu, Min‐Yi Lv, Zerong Cai, Yifeng Zou, Ping Lan, Xiaojian Wu, Feng Gao · 2021 · Molecular Medicine
48. Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer
    Jen‐Pin Chuang, Hsiang‐Lin Tsai, Po-Jung Chen, Tsung‐Kun Chang, Wei‐Chih Su, Yung‐Sung Yeh, Ching‐Wen Huang, Jaw‐Yuan Wang · 2022 · Cells
49. ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-β axis in colorectal cancer
    Jiayang Liu, Zhao Huang, Hai‐Ning Chen, Siyuan Qin, Yan Chen, Jingwen Jiang, Zhe Zhang, Maochao Luo, Qin Ye, Na Xie et al. · 2021 · Oncogene
50. Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions
    John Berry, Timothy J. Vreeland, Alfred Francois Trappey, Diane F. Hale, Kaitlin M. Peace, Joshua A. Tyler, Avery S. Walker, Ramon A. Brown, Garth S. Herbert, Fia Yi et al. · 2016 · Expert Review of Clinical Immunology
51. CT-Based Radiomics Signature: A Potential Biomarker for Predicting Postoperative Recurrence Risk in Stage II Colorectal Cancer
    Shuxuan Fan, Xiaonan Cui, Chunli Liu, Xubin Li, Lei Zak Zheng, Qian Song, Jin Qi, Wenjuan Ma, Zhaoxiang Ye · 2021 · Frontiers in Oncology
52. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial
    Clélia Coutzac, Frédéric Bibeau, Méher Ben Abdelghani, Thomas Aparicio, Romain Cohen, Elodie Coquan, Olivier Dubreuil, Ludovic Evesque, François Ghiringhelli, Stefano Chong Hun Kim et al. · 2022 · Digestive and Liver Disease
53. Circulating Tumor DNA as a Real-Time Biomarker for Minimal Residual Disease and Recurrence Prediction in Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis
    Silvia Negro, Alessandra Pulvirenti, Chiara Trento, Stefano Indraccolo, Stefania Ferrari, Marco Scarpa, Emanuele Damiano Luca Urso, Francesca Bergamo, Salvatore Pucciarelli, Simona Deidda et al. · 2025 · International Journal of Molecular Sciences
54. What We Know About Stage II and III Colon Cancer: It’s Still Not Enough
    Alberto Puccini, Martin D. Berger, Wu Zhang, Heinz‐Josef Lenz · 2017 · Targeted Oncology
55. Molecular Markers for Colorectal Cancer
    Moriah Wright, Jenifer S. Beaty, Charles A. Ternent · 2017 · Surgical Clinics of North America
56. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer
    Julie L. Koenig, Diego A.S. Toesca, Jeremy Phillip Harris, Chiaojung Jillian Tsai, Sigurdís Haraldsdóttir, Albert Y. Lin, Erqi Liu Pollom, Daniel Tandel Chang · 2019 · American Journal of Clinical Oncology
57. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
    Yaqi Li, Qianlan Yao, Long Zhang, Shaobo Mo, Sanjun Cai, Dan Huang, Junjie Peng · 2020 · The Oncologist
58. Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer
    Jonathan M. Loree, Aaron Sha, Maryam Soleimani, Hagen Fritz Kennecke, Maria Yi Ho, Winson Y. Cheung, Karen E. Mulder, Shirin Abadi, Jennifer L. Spratlin, Sharlene Gill · 2018 · Clinical Colorectal Cancer
59. Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape
    Mark A. Glaire, Neil A. J. Ryan, Marieke E. Ijsselsteijn, Katarzyna Kedzierska, Sofia Obolenski, Reem Ali, Emma Jayne Crosbie, Tjalling Bosse, Noel F.C.C. de Miranda, David N. Church · 2022 · The Journal of Pathology
60. Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability—Lessons from Colorectal Cancer
    Luana Greco, Federica Rubbino, Arianna Dal Buono, Luigi Laghi · 2023 · Genes
61. Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials
    Lizhen Zhu, Caixia Dong, Ying Cao, Xuefeng Fang, Chenhan Zhong, Dan Li, Ying Yuan · 2016 · PLoS ONE
62. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer
    Xingli Fu, Zheng Fang, Liang-Hui Shu, Guo‐Qing Tao, Jianqiang Wang, Zhilian Rui, Yongjie Zhang, Zhiqiang Tian · 2017 · Oncotarget
63. Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/β-catenin signaling
    Kun Zhang, Minhui Li, Houyi Huang, Linpeng Li, Jie Yang, Li Feng, Junjie Gou, Mengju Jiang, Liaotian Peng, Linyi Chen et al. · 2017 · Oncotarget
64. miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
    Kha Wai Hon, Nadiah Abu, Nurul‐Syakima Ab Mutalib, Rahman A Jamal · 2018 · Frontiers in Pharmacology
65. Syndrome de Lynch : quoi de neuf ?
    Anna Pellat, Jeanne Netter, Géraldine Perkins, Romain Cohen, Florence Coulet, Yann R. Parc, Magali Svrcek, Alex Duval, Thierry André · 2018 · Bulletin du Cancer
66. Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer
    Kate Jessica Wilkinson, Weng Leong Ng, Tara Laurine Roberts, Therese M. Becker, Stephanie Hui-Su Lim, Wei Ming Chua, Cheok Soon Lee · 2021 · Journal of Clinical Pathology
67. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
    Sakti Chakrabarti, Anup Kasi, Aparna R. Parikh, Amit Mahipal · 2022 · Cancers
68. Tumor location as a novel high risk parameter for stage II colorectal cancers
    Biyuan Wang, Jiao Yang, Shuting Li, Meng Lv, Zheling Chen, Enxiao Li, Min Yi, Jin Yang · 2017 · PLoS ONE
69. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials
    Claire Gallois, Qian Shi, Levi Pederson, Thierry André, Timothy J. Iveson, Alberto F. Sobrero, Steven R. Alberts, Aimery de Gramont, Jeffrey A. Meyerhardt, Thomas J. George et al. · 2024 · Journal of Clinical Oncology
70. Cardamonin reduces chemotherapy resistance of colon cancer cells via the TSP50/NF‑κB pathway in�vitro
    Sen Lu, Caizhao Lin, Xiao-bin Cheng, Hanju Hua, Tao Xiang, Yu Huang, Xi Huang · 2018 · Oncology Letters
71. Prognostic value of the combination of microsatellite instability and BRAF mutation in colorectal cancer
    Yingchi Yang, Dong Wang, Lan Jin, Guocong Wu, Zhigang Bai, Jin Wang, Hongwei Yao, Zhongtao Zhang · 2018 · Cancer Management and Research
72. Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer:Post hocAnalysis of the MOSAIC and PETACC-8 Trials
    Édouard Auclin, Julien Taı̈eb, Côme Lepage, Thomas Aparicio, Roger Faroux, Enrico Mini, Gunnar Folprecht, Ramón Salazar, Magdalena Benetkiewicz, Maria Chiara Banzi et al. · 2019 · Cancer Epidemiology Biomarkers & Prevention
73. Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer
    De‐Shen Wang, Zhi‐Qiang Wang, Gong Chen, Jiewen Peng, Wei Wang, Yanhong Deng, Feng Wang, Jian‐wei Zhang, Han‐lin Liang, Fen Feng et al. · 2019 · Cancer Medicine
74. Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database
    Pietro Achilli, Jacopo Crippa, Fabian Grass, Kellie Leanne Mathis, Anne-Lise D. D’Angelo, Mohamed A. Abd El Aziz, Courtney N. Day, William Scott Harmsen, David W. Larson · 2020 · International Journal of Cancer
75. Applications of Liquid Biopsy for Surgical Patients With Cancer
    Kelly M. Mahuron, Yuman Fong · 2023 · JAMA Surgery
76. A Tumor-Naïve ctDNA Assay Detects Minimal Residual Disease in Resected Stage II or III Colorectal Cancer and Predicts Recurrence: Subset Analysis from the GALAXY Study in CIRCULATE-Japan
    Yoshiaki Nakamura, Kristiyana Kaneva, Christine Lo, Daniel S. Neems, Jonathan E. Freaney, Hala Boulos, Seung Won Hyun, Farahnaz Islam, Jason Yamada-Hanff, Terri M. Driessen et al. · 2024 · Clinical Cancer Research
77. Explainable artificial intelligence in high-throughput drug repositioning for subgroup stratifications with interventionable potential
    Zainab Al-Taie, Danlu Liu, Jonathan B. Mitchem, Christos Papageorgiou, Jussuf T. Kaifi, Wesley C. Warren, Chi‐Ren Shyu · 2021 · Journal of Biomedical Informatics
78. Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
    Yu Song, Qianqian Mao, Manling Zhou, Cheng-Jiang Liu, Li Kong, Ting Hu · 2024 · BMC Gastroenterology
79. Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer
    Wenjun Hu, Linping Lei, Xuqin Xie, Libin Huang, Qian Cui, Tang Dang, Gang Logan Liu, Yuan Li, Xiao‐Feng Sun, Zong‐Guang Zhou · 2019 · Cell Death and Disease
80. PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification
    Pablo Azcue, Ignacio Encı́o, David Guerrero Setas, Javier Suárez, Arkaitz Galbete, María Mercado, Ruth Vera, María Luisa Gómez Dorronsoro · 2021 · Cancers
81. Tumor‐associated macrophages and risk of recurrence in stage III colorectal cancer
    Tommaso Cavalleri, Luana Greco, Federica Rubbino, Tsuyoshi Hamada, Maria Quaranta, Fabio Grizzi, Elisabetta Sauta, Vincenzo Craviotto, Paola Bossi, Stefania Vetrano et al. · 2022 · The Journal of Pathology Clinical Research
82. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target
    Gaurav Goyal, Tiffany Fan, Peter T. Silberstein · 2016 · Familial Cancer
83. The Curcumin Analogue, MS13 (1,5-Bis(4-hydroxy-3- methoxyphenyl)-1,4-pentadiene-3-one), Inhibits Cell Proliferation and Induces Apoptosis in Primary and Metastatic Human Colon Cancer Cells
    Nor Isnida Ismail, Iekhsan Othman, Faridah Abas, Nordin H. Lajis, Rakesh Naidu · 2020 · Molecules
84. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer
    Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P. et al. · 2020 · BMC Cancer
85. Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review
    Angela Damato, Michele Ghidini, Lorenzo Dottorini, Gianluca Tomasello, Alessandro Iaculli, Antonio Ghidini, Andrea Luciani, Fausto Petrelli · 2023 · Current Oncology Reports
86. Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR)
    Thierry Lecomte, David Tougeron, Romain Chautard, Diane Bressand, Frédéric Bibeau, Benjamin Blanc, Romain Cohen, Jérémie Jacques, Jean-Paul Lagasse, Pierre Laurent‐Puig et al. · 2024 · Digestive and Liver Disease
87. Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer
    Oluseyi Abidoye, Daniel H. Ahn, Mitesh J. Borad, Christina Wu, Tanios Bekaii‐Saab, Sakti Chakrabarti, Mohamad Bassam Sonbol · 2025 · Cells
88. HNF1A regulates colorectal cancer progression and drug resistance as a downstream of POU5F1
    Shiki Fujino, Norikatsu Miyoshi, Aya Ito, Masayoshi Yasui, Chu Matsuda, Masayuki Ohue, Mamoru Uemura, Tsunekazu Mizushima, Yuichiro� Doki, Hidetoshi Eguchi · 2021 · Scientific Reports
89. Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer
    Paula Pellenz Tomasini, Temenouga Nikolova Guecheva, Natalia Motta Leguisamo, Sarah Péricart, Anne‐Cécile Brunac, Jean‐Sébastien Hoffmann, Jenifer Saffi · 2021 · Cancers
90. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
    Émilie Moati, Valérie Taly, Simon Garinet, Audrey Didelot, Julien Taı̈eb, Pierre Laurent‐Puig, Aziz Zaanan · 2021 · Cancers
91. Aerobic glycolysis in colon cancer is repressed by naringin via the HIF1A pathway
    Guangtao Pan, Ping Zhang, Aiying Chen, Yu Deng, Zhen Zhang, Lu Han, Aoxun Zhu, Cong Zhou, Yanran Wu, Sen Li · 2023 · Journal of Zhejiang University SCIENCE B
92. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial
    Édouard Auclin, Thierry André, Julien Taı̈eb, Maria Chiara Banzi, Jean‐Luc Van Laethem, Josep M. Tabernero, Tamas Hickish, Aimery de Gramont, Déwi Vernerey · 2019 · British Journal of Cancer
93. De-escalating chemotherapy for stage II colon cancer?
    Jianfei Fu, Lunpo Wu, Chenyang Ge, Tiantian Xu, Dan Li, Wei Fu, Liangjing Wang, Jinlin Du · 2019 · Therapeutic Advances in Gastroenterology
94. Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRASG12D glycolytic colorectal tumors
    Marlies C. Ludikhuize, Sira Gevers, Nguyen BT Nguyen, Maaike Meerlo, S. Khadijeh Shafiei Roudbari, M. Can Gülersönmez, Edwin C.A. Stigter, Jarno Drost, Hans C. Clevers, Boudewijn M.T. Burgering et al. · 2022 · Communications Biology
95. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based study
    Elizabeth Alwers, Lina Jansen, Hendrik Bläker, Matthias Kloor, Katrin Elisabeth Tagscherer, Wilfried Roth, Daniel Boakye, Esther Herpel, Carsten Grüllich, Jenny Chang‐Claude et al. · 2019 · Molecular Oncology
96. The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer
    Yu Fu, Xiaowan Chen, Yongxi Song, Xuanzhang Huang, Quan Chen, Xinger Lv, Peng Gao, Zhenning Wang · 2021 · BMC Cancer
97. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer—results from the RAPIDO trial
    Esmée A. Dijkstra, W.H. Zwart, Per Johan Nilsson, Hein Putter, Annet G.H. Roodvoets, Elma Meershoek‐Klein Kranenbarg, Jan‐Erik Frödin, Peter Nygren, Lars Jørgen Østergaard, Christian Kersten et al. · 2023 · ESMO Open
98. Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer
    Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S. Kim, Corey Lipchik, Patrick G. Gavin, Greg Yothers, Carmen Joseph Allegra, Nicholas James Petrelli et al. · 2024 · Journal of Clinical Oncology
99. Updates on the Management of Colorectal Cancer in Older Adults
    Colin O'Donnell, Joleen Marie Hubbard, Zhaohui Jin · 2024 · Cancers
100. A comprehensive overview of promising biomarkers in stage II colorectal cancer
     Pauline Parent, Romain Cohen, Elie Rassy, Magali Svrcek, Julien Taı̈eb, Thierry André, Anthony Turpin · 2020 · Cancer Treatment Reviews